Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2015 Jan;17(1):3-17.
doi: 10.1016/j.jcyt.2014.05.019. Epub 2014 Jul 28.

Cellular immunotherapy for pediatric solid tumors

Meenakshi Hegde  1 , Alexander J Moll  2 , Tiara T Byrd  3 , Chrystal U Louis  4 , Nabil Ahmed  5
Affiliations
Review

Cellular immunotherapy for pediatric solid tumors

Meenakshi Hegde et al. Cytotherapy. 2015 Jan.

Abstract

Substantial progress has been made in the treatment of pediatric solid tumors over the past 4 decades. However, children with metastatic and or recurrent disease continue to do poorly despite the aggressive multi-modality conventional therapies. The increasing understanding of the tumor biology and the interaction between the tumor and the immune system over the recent years have led to the development of novel immune-based therapies as alternative options for some of these high-risk malignancies. The safety and anti-tumor efficacy of various tumor vaccines and tumor-antigen specific immune cells are currently being investigated for various solid tumors. In early clinical trials, most of these cellular therapies have been well tolerated and have shown promising clinical responses. Although substantial work is being done in this field, the available knowledge for pediatric tumors remains limited. We review the contemporary early phase cell-based immunotherapy efforts for pediatric solid tumors and discuss the rationale and the challenges thereof.

Keywords: T cell; cell therapy; pediatric solid tumor; vaccine.

PubMed Disclaimer

Conflict of interest statement

Disclosure of interests: The Center for Cell and Gene Therapy in engaged in a research collaboration with Celgene Inc, administered by Baylor College of Medicine, to develop chimeric antigen receptor–based therapeutics that is. CUL holds patents with or receives royalties from Cell Medica. MH and NA have patent applications in the field of T-cell and gene-modified T-cell therapy for cancer.

References

    1. Orentas RJ, Lee DW, Mackall C. Immunotherapy targets in pediatric cancer. Front Oncol. 2012;2:3. - PMC - PubMed
    1. Rock KL, Gamble S, Rothstein L. Presentation of exogenous antigen with class I major histocompatibility complex molecules. Science. 1990;249:918–21. - PubMed
    1. Capitini CM, Mackall CL, Wayne AS. Immune-based therapeutics for pediatric cancer. Expert Opin Biol Ther. 2010;10:163–78. - PMC - PubMed
    1. Eshhar Z, Waks T, Gross G, Schindler DG. Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors. Proc Natl Acad Sci U S A. 1993;90:720–4. - PMC - PubMed
    1. Carpenito C, Milone MC, Hassan R, Simonet JC, Lakhal M, Suhoski MM, et al. Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains. Proc Natl Acad Sci U S A. 2009;106:3360–5. - PMC - PubMed

Publication types

MeSH terms